221 related articles for article (PubMed ID: 23716537)
21. Brentuximab vedotin in the treatment of CD30+ PTCL.
Barta SK; Gong JZ; Porcu P
Blood; 2019 Dec; 134(26):2339-2345. PubMed ID: 31697814
[TBL] [Abstract][Full Text] [Related]
22. [Molecular pathogenesis of peripheral T cell lymphoma (2): extranodal NK/T cell lymphoma, nasal type, adult T cell leukemia/lymphoma and enteropathy associated T cell lymphoma].
Couronné L; Bastard C; Gaulard P; Hermine O; Bernard O
Med Sci (Paris); 2015 Nov; 31(11):1023-33. PubMed ID: 26576610
[TBL] [Abstract][Full Text] [Related]
23. CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies.
Geissinger E; Bonzheim I; Roth S; Rosenwald A; Müller-Hermelink HK; Rüdiger T
Leuk Lymphoma; 2009 Jun; 50(6):1010-6. PubMed ID: 19479612
[TBL] [Abstract][Full Text] [Related]
24. CXCR4/CD184 immunoreactivity in T-cell non-Hodgkin lymphomas with an overall Th1- Th2+ immunophenotype.
Weng AP; Shahsafaei A; Dorfman DM
Am J Clin Pathol; 2003 Mar; 119(3):424-30. PubMed ID: 12645345
[TBL] [Abstract][Full Text] [Related]
25. Nuclear Factor kappa B is central to Marek's disease herpesvirus induced neoplastic transformation of CD30 expressing lymphocytes in-vivo.
Kumar S; Kunec D; Buza JJ; Chiang HI; Zhou H; Subramaniam S; Pendarvis K; Cheng HH; Burgess SC
BMC Syst Biol; 2012 Sep; 6():123. PubMed ID: 22979947
[TBL] [Abstract][Full Text] [Related]
26. JAK2 Rearrangements Are a Recurrent Alteration in CD30+ Systemic T-Cell Lymphomas With Anaplastic Morphology.
Fitzpatrick MJ; Massoth LR; Marcus C; Vergilio JA; Severson E; Duncan D; Ramkissoon SH; Hasserjian RP; Kim AS; Sohani AR; Williams EA; Nardi V
Am J Surg Pathol; 2021 Jul; 45(7):895-904. PubMed ID: 34105517
[TBL] [Abstract][Full Text] [Related]
27. [Nasal and pharyngeal non-Hodgkin lymphomas and their relationship with Epstein-Barr virus: a report of 158 cases].
He YJ; Jia XS; Hasui K; Wang EH; He AG
Zhonghua Bing Li Xue Za Zhi; 2007 Feb; 36(2):94-7. PubMed ID: 17493382
[TBL] [Abstract][Full Text] [Related]
28. Classification of cytotoxic T-cell and natural killer cell lymphomas.
Jaffe ES; Krenacs L; Raffeld M
Semin Hematol; 2003 Jul; 40(3):175-84. PubMed ID: 12876666
[TBL] [Abstract][Full Text] [Related]
29. CD30 expression in a case of intravascular large B-cell lymphoma, cutaneous variant.
Provasi M; Bagnoli F; Fanoni D; Alberti-Violetti S; Tomasini D; Berti E
J Cutan Pathol; 2019 Jun; 46(6):447-451. PubMed ID: 30779218
[TBL] [Abstract][Full Text] [Related]
30. CD30-positive cutaneous extranodal natural killer/T-cell lymphoma: clinicopathological features and survival outcomes.
Lee WJ; Moon IJ; Shin HJ; Won CH; Chang SE; Choi JH; Lee MW
Int J Dermatol; 2019 Jun; 58(6):688-696. PubMed ID: 30597548
[TBL] [Abstract][Full Text] [Related]
31. [Splenic T-cell and NK-cell lymphomas: a clinicopathologic and immunophenotypic analysis of 9 cases].
Li Z; Liu WP; Tang Y; Jiang LL; Zhang WY; Bi CF; Li GD
Zhonghua Xue Ye Xue Za Zhi; 2007 Apr; 28(4):217-22. PubMed ID: 17877195
[TBL] [Abstract][Full Text] [Related]
32. Epstein-Barr virus-associated primary nodal T/NK-cell lymphoma shows a distinct molecular signature and copy number changes.
Ng SB; Chung TH; Kato S; Nakamura S; Takahashi E; Ko YH; Khoury JD; Yin CC; Soong R; Jeyasekharan AD; Hoppe MM; Selvarajan V; Tan SY; Lim ST; Ong CK; Nairismägi ML; Maheshwari P; Choo SN; Fan S; Lee CK; Chuang SS; Chng WJ
Haematologica; 2018 Feb; 103(2):278-287. PubMed ID: 29097495
[TBL] [Abstract][Full Text] [Related]
33. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
Shea L; Mehta-Shah N
Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
[TBL] [Abstract][Full Text] [Related]
34. Granzyme B-expressing peripheral T-cell lymphomas: neoplastic equivalents of activated cytotoxic T cells with preference for mucosa-associated lymphoid tissue localization.
de Bruin PC; Kummer JA; van der Valk P; van Heerde P; Kluin PM; Willemze R; Ossenkoppele GJ; Radaszkiewicz T; Meijer CJ
Blood; 1994 Dec; 84(11):3785-91. PubMed ID: 7524749
[TBL] [Abstract][Full Text] [Related]
35. CD30 Expression by B and T Cells: A Frequent Finding in Angioimmunoblastic T-Cell Lymphoma and Peripheral T-Cell Lymphoma-Not Otherwise Specified.
Onaindia A; Martínez N; Montes-Moreno S; Almaraz C; Rodríguez-Pinilla SM; Cereceda L; Revert JB; Ortega C; Tardio A; González L; García S; Camacho FI; González-Vela C; Piris MA
Am J Surg Pathol; 2016 Mar; 40(3):378-85. PubMed ID: 26574847
[TBL] [Abstract][Full Text] [Related]
36. CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells.
Gruss H-J ; Herrmann F
Leuk Lymphoma; 1996 Feb; 20(5-6):397-409. PubMed ID: 8833395
[TBL] [Abstract][Full Text] [Related]
37. High intratumoural galectin-1 expression predicts adverse outcome in ALK
Holst JM; Ludvigsen M; Hamilton-Dutoit SJ; Bendix K; Plesner TL; Nørgaard P; Møller MB; Steiniche T; Rabinovich GA; d'Amore F; Pedersen MB
Hematol Oncol; 2020 Feb; 38(1):59-66. PubMed ID: 31834627
[TBL] [Abstract][Full Text] [Related]
38. Cutaneous peripheral T-cell lymphoma of cytotoxic phenotype mimicking extranodal NK/T-cell lymphoma.
Pan ST; Chang WS; Murphy M; Martinez A; Chuang SS
Am J Dermatopathol; 2011 Apr; 33(2):e17-20. PubMed ID: 21252637
[TBL] [Abstract][Full Text] [Related]
39. Phenotypic and cytotoxic characteristics of peripheral T-cell and NK-cell lymphomas in relation to Epstein-Barr virus association.
Chan AC; Ho JW; Chiang AK; Srivastava G
Histopathology; 1999 Jan; 34(1):16-24. PubMed ID: 9934580
[TBL] [Abstract][Full Text] [Related]
40. CD69 expression correlates with expression of other markers of Th1 T cell differentiation in peripheral T cell lymphomas.
Dorfman DM; Shahsafaei A
Hum Pathol; 2002 Mar; 33(3):330-4. PubMed ID: 11979374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
